Latest Temporal lobe epilepsy Stories
Screening drugs that work against defects in the tiny pores or channels that allow calcium to flow in and out cells is already easier because of a specially bred mouse that has the "pure" form of absence seizures (brief lapses in consciousness) usually seen in children, said researchers at Baylor College of Medicine in a report that appears in the current issue of the Journal of Neuroscience.
- New antiepileptic drug with novel mechanism of action helps address critical unmet medical need for many people living with uncontrolled epilepsy - Vimpat(R) offers hope to people with epilepsy who still have uncontrolled partial onset seizures with current treatment ATLANTA, May 26 /PRNewswire/ -- press release, regulated information - UCB today announced that Vimpat(R) (lacosamide) C-V, a new antiepileptic drug (AED) is available in the U.S.
- Vimpat(R) demonstrated greater seizure reduction and improved seizure freedom versus placebo when added to first and second-generation antiepileptic drugs (AEDs) - Phase III study supports recent U.S. FDA and European Commission approvals of Vimpat(R) ATLANTA, Jan.
* New antiepileptic drug with a novel mechanism of action * Vimpat(R) helped people with epilepsy who still had uncontrolled partial onset seizures with current treatment * Vimpat(R) will be available in the U.S.
Belgium-based biopharmaceutical and specialty chemical company UCB has announced that the European Commission has approved Vimpat as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalization in patients with epilepsy aged 16 years and older.
First New Epilepsy Treatment for Partial-Onset Seizures in Three Years * A novel mode of action * Improved seizure control when added to a wide range of antiepileptic drugs * High long-term retention rate * Multiple formulations for ease of use * Soon to be launched in Germany and the UK Brussels, BELGIUM - September 3, 2008 at 7:00 am CEST - press release, regulated information: UCB announced today that the European Commission (EC) has approved Vimpat(R) (lacosamide) as...
Press release: regulated information UCB announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion recommending that the European Commission grants a marketing authorisation for lacosamide, proposed trade name Vimpat(TM), for the adjunctive treatment of partial onset seizures with or without secondary generalisation in patients with epilepsy, aged 16 years and older.
By ED SUSMAN So-called Gamma Knife surgery -- focusing radiation to one point in the brain -- offers an alternative to open surgery for one of the most common forms of epilepsy.
NEW YORK (Reuters Health) - In patients with epilepsy that does not respond to drug therapy, and who also have depression or anxiety, surgery to treat the epilepsy often results in improvements in psychiatric symptoms, according to results of a multicenter study.